SYNTHETIC ANALOGS OF XANTHOHUMOL

CATEGORY

Class C07D 
 

AVAILABILITY

Available
 

PATENT PHASE

Recognised patent no.0001416855 dated 20/7/2015   
 

INVENTOR

Dr Adriana Albini - no longer pertaining to the Authority
Dr Desirée Bartolini – no longer pertaining to the Authority
 

FIELD OF INTEREST

The present invention relates to new synthetic analogs of Xanthohumol (XN), a prenylated chalcone of natural origin contained in hops (Humulus Lupulus).

DESCRIPTION

As demonstrated by numerous studies, diet can affect individuals’ state of health. For this reason natural compounds extracted from plants are increasingly subject to analysis for use as supplements and in association with conventional therapy. The most studied compounds include flavonoids, which have displayed chemopreventive or therapeutic properties in various diseases. These molecules include Xanthohumol (XN), the main chalcone contained in the female inflorescences of the hops plant (Humulus Lupulus L. - Cannabaceae). This molecule has been widely studied for its multiple activities, including anti-invasive, antiproliferative, antiangiogenic, pro-apoptotic and anti-bacterial properties, its inhibitory action on the enzymes of cytochrome P450 involved in the metabolic activation of carcinogenesis, and anti-inflammatory properties, exerted through the reduction of nitric oxide (NO) production.
Unfortunately, due to the poor power and selectivity of action of XN and its synthetic analogs known to date, there remains a need to identify new molecules that are more effective in degenerative processes characterised by cell hyperproliferation, angiogenesis, destruction of tissues due to uncontrolled hyperproteolysis and that can demonstrate improved properties in terms of bioavailability, efficacy and reduced toxicity with respect to what is known.

The present patent focuses on the production of synthetic analogs of XN that can improve the characteristics of natural XN; in particular, the compounds of the invention are provided with antiangiogenic, antioxidant and chemopreventive properties and their anti-proliferative, anti-invasive and antiangiogenic activity is greater than the natural compound.
A further object of the present invention is the use of the compounds according to the invention as medication. In particular, the compounds according to the invention can be used in the prevention and/or treatment of cancer, inflammatory, cardiovascular or neurodegenerative diseases, or as inhibitors of angiogenesis, e.g. in the prevention and/or treatment of tumoural angiogenesis.
Finally, the compounds according to the patent can be appropriately formulated with excipients or pharmaceutically acceptable carriers.

HOLDER

AUSL-IRCCS with registered office in Via Amendola n. 2 in Reggio Emilia joint holder with the University of PISA with 50% each.

 

DOCUMENTS

Patent certificate. Transcription for authority merger.